Roger Green is joined by co-host Jörn Schattenberg to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This conversation also features comments around the subject of new NAFLD/NASH nomenclature.
Roger Green is joined by KOL Mazen Noureddin to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This final interview with Mazen is to be followed by a series of deep-dive episodes dedicated to unpacking the 2023 EASL Congress and the 83rd annual American Diabetes Association Scientific Sessions. Stay safe and surf on!
Roger Green is joined by KOL Mazen Noureddin to discuss a complex and developing NASH therapeutic landscape and takeaways from an exciting month of meetings. This is the first conversation of a series of deep-dive episodes dedicated to unpacking the 2023 EASL Congress and the 83rd annual American Diabetes Association Scientific Sessions.
Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this final conversation the panelists revisit some of the more interesting moments of the meeting before answering a question around what takeaways will reshape the way we think and act moving forward.
Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this conversation each panelist revisits the posters and presentations they found compelling. As expected from such a diverse group, the discussion touches on a range of fascinating topics all worth consideration.
Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this conversation, the panelists discuss scoring systems used to evaluate NASH.
Hannes Hagström, Michelle Long, Rachel Zayas, Jeff McIntyre, Michael Betel and Roger Green get together for an in-depth wrap-up session on EASL Congress 2023. In this first of four conversations, the panelists share their initial impressions before diving into the implications of the new nomenclature rollout.
Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. This final conversation around days 1-3 explores the landscape of AI in the context of better understanding liver diseases. The group also discusses FGF-21 agents, NAIL-NIT data and more.
Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. In this conversation the group discusses a session that Jörn co-chaired on challenges in screening patients for fatty liver diseases. Notes touch on how time restrictions obstruct frontline treaters from offering both adequate screening and support lifestyle interventions simultaneously. The group goes on to consider the potential of dual agonists efinopegdutide and pemvidutide.
Surfing NASH conducted on-site coverage from EASL Congress 2023 in Vienna with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green. In this conversation the group shares their initial impressions of the first three days of the meeting. Notably, they explore Stephen Harrison’s presentation of the highly anticipated MAESTRO-NASH Phase 3 results.
